Copyright
©The Author(s) 2022.
World J Gastroenterol. Jul 14, 2022; 28(26): 3218-3231
Published online Jul 14, 2022. doi: 10.3748/wjg.v28.i26.3218
Published online Jul 14, 2022. doi: 10.3748/wjg.v28.i26.3218
Table 1 Pre-liver transplant clinical and laboratory variables
Total (n = 176) | BMI groups after ascites correction | P value | ||
Overweight or obese (n = 122) | Underweight or normal (n = 54) | |||
Age at listing, median (range) years | 61.0 (32.0–71.4) | 60.3 (32.0–71.4) | 61.6 (45.2–71.0) | 0.048a |
Age at end of listing, median (range) years | 61.0 (32.0–72.0) | 61.0 (32.0–71.0) | 62.0 (48.0–72.0) | 0.09 |
Female sex, n (%) | 81 (46.02) | 53 (43.44) | 28 (51.85) | 0.30 |
Height at listing, median (range) cm | 168.0 (148.0–193.0) | 168.0 (148.0–188.0) | 168.0 (150.0–193.0) | 0.23 |
Weight at listing, median (range) kg | 88.3 (39.6–146.5) | 94.9 (69.0–146.5) | 72.0 (39.6–94.2) | < 0.001c |
Ascites adjusted weight at listing, median (range) kg | 77.4 (33.7–140.0) | 85.1 (60.5–140.0) | 64.4 (33.7–80.1) | < 0.001c |
Weight at end of listing, median (range) kg | 86.9 (39.6–161.8) | 92.9 (50.7–161.8) | 73.9 (39.6–94.2) | < 0.001c |
BMI at listing, median (range) kg/m2 | 31.0 (17.6–48.9) | 33.7 (25.6–48.9) | 25.4 (17.6–30.8) | < 0.001c |
Ascites adjusted BMI at listing, median (range) kg/m2 | 27.4 (15.0–45.3) | 29.2 (25.0–45.3) | 22.6 (15.0–24.9) | < 0.001c |
Na MELD (at listing), median (range) | 22.0 (10.0–48.0) | 21.0 (11.0–48.0) | 22.0 (10.0–43.0) | 0.34 |
Na MELD at end of listing, median (range) | 23.0 (6.0–45.0) | 23.0 (6.0–44.0) | 23.0 (10.0–45.0) | 0.41 |
Creatinine at listing, median (range) μmol/L | 98.5 (51.0–564.0) | 96.5 (55.0–564.0) | 103.0 (51.0–399.0) | 0.50 |
Creatinine at end of listing, median (range) μmol/L | 112.5 (44.0–719.0) | 115.0 (44.0–719.0) | 109.0 (49.0–483.0) | 0.50 |
eGFR at listing, median (range) mL/min/1.73 m2 | 63.0 (17.0–120.0) | 65.5 (18.0–117.0) | 56.0 (17.0–120.0) | 0.11 |
eGFR at end of listing, median (range) mL/min/1.73 m2 | 52.5 (17.0–116.0) | 57.0 (17.0–116.0) | 48.0 (20.0–98.0) | 0.017a |
Bilirubin at listing, median (range) μmol/L | 49.0 (8.0–955.0) | 51.0 (8.0–755.0) | 45.5 (14.0–955.0) | 0.11 |
Bilirubin at end of listing, median (range) μmol/L | 56.5 (3.0–927.0) | 58.0 (8.0–927.0) | 50.0 (3.0–802.0) | 0.19 |
INR at listing, median (range) | 1.5 (1.1–4.7) | 1.5 (1.1–4.7) | 1.5 (1.1–3.9) | 0.05 |
INR at end of listing, median (range) | 1.7 (1.1–7.6) | 1.7 (1.1–7.6) | 1.8 (1.1–5.0) | 0.46 |
Na at listing, median (range) mEq/L | 134.0 (116.0–147.0) | 135.0 (120.0–147.0) | 133.0 (116.0–142.0) | 0.014a |
Na at end of listing, median (range) mEq/L | 135.0 (116.0–159.0) | 135.0 (116.0–159.0) | 134.0 (120.0–152.0) | 0.10 |
Albumin at listing, median (range) g/L | 30.5 (9.0 – 47.0) | 29.5 (20.0–47.0) | 31.0 (9.0–42.0) | 0.08 |
Albumin at end of listing, median (range) g/L | 30.0 (10.0–54.0) | 30.0 (12.0–54.0) | 30.0 (10.0–50.0) | 0.28 |
Frailty score (n = 159), median (range) | 4.0 (2.0–8.0) | 4.0 (2.0–8.0) | 5.0 (3.0–8.0) | 0.25 |
None to mild, n (%) | 116 (72.96) | 78 (71.56) | 38 (76) | 0.56 |
Moderate to severe, n (%) | 43 (27.04) | 31 (28.44) | 12 (24) | |
Missing, n (%) | 17 (9.66) | 13 (10.66) | 4 (7.41) | |
Encephalopathy, n (%) | 141 (80.11) | 99 (81.15) | 42 (77.78) | 0.61 |
Ascites, n (%) | 161 (91.48) | 109 (089.34) | 052 (096.30) | 0.15 |
Degree of ascites, n (%) | ||||
None | 14 (07.95) | 13 (10.66) | 1 (1.85) | 0.030a |
Mild | 41 (23.30) | 30 (24.59) | 11 (20.37) | |
Moderate | 30 (17.05) | 24 (019.67) | 6 (11.11) | |
Severe | 91 (51.70) | 55 (45.08) | 36 (66.67) | |
Need for LVP, n (%) | 103 (58.86) | 64 (52.89) | 39 (72.22) | 0.016a |
SBP, n (%) | 46 (26.44) | 33 (27.05) | 13 (25.00) | 0.78 |
Variceal bleed, n (%) | 53 (30.11) | 34 (27.87) | 19 (35.19) | 0.33 |
Hepatorenal syndrome, n (%) | 48 (27.27) | 30 (24.59) | 18 (33.33) | 0.23 |
Hypertension, n (%) | 80 (45.45) | 58 (47.54) | 22 (40.74) | 0.40 |
Diabetes, n (%) | 104 (59.09) | 68 (55.74) | 36 (66.67) | 0.17 |
Hyperlipidemia, n (%) | 57 (32.39) | 35 (28.69) | 22 (40.74) | 0.12 |
CKD, n (%) | 18 (10.23) | 12 (9.84) | 6 (11.11) | 0.80 |
CAD, n (%) | 29 (16.48) | 22 (18.03) | 7 (12.96) | 0.40 |
Time on waiting list, median (range) days | 136.0 (1.0–1566.0) | 139.5 (1.0–1497.0) | 117.0 (1.0–1566.0) | 0.42 |
ICU stay within 90 d before end of listing, n (%) | 30 (17.05) | 21 (17.21) | 9 (16.67) | 0.93 |
No of hospitalizations within 90 d before end of listing, median (range), n (%) | 1.0 (0.0–5.0) | 1.0 (0.0–5.0) | 1.0 (0.0–5.0) | 0.42 |
< 2 | 151 (85.80) | 105 (86.07) | 46 (85.19) | 0.88 |
≥ 2 | 25 (14.20) | 17 (13.93) | 8 (14.81) | |
Bacteraemia/sepsis within 90 d before end of listing, n (%) | 19 (11.66) | 12 (10.62) | 7 (14.00) | 0.54 |
Outcome, n (%) | ||||
Active living | 1 (0.57) | 1 (0.82) | 0 (00) | 0.26 |
De-listed | 22 (12.50) | 14 (11.48) | 8 (14.81) | |
Died | 42 (23.86) | 25 (20.49) | 17 (31.48) | |
Transplanted | 111 (63.07) | 82 (67.21) | 29 (53.70) | |
Type of LT received, n (%) | ||||
DDLT | 78 (70.27) | 57 (69.51) | 21 (72.41) | 0.77 |
LDLT | 33 (29.73) | 25 (30.49) | 8 (27.59) |
- Citation: Qazi-Arisar FA, Uchila R, Chen C, Yang C, Chen SY, Karnam RS, Azhie A, Xu W, Galvin Z, Selzner N, Lilly L, Bhat M. Divergent trajectories of lean vs obese non-alcoholic steatohepatitis patients from listing to post-transplant: A retrospective cohort study. World J Gastroenterol 2022; 28(26): 3218-3231
- URL: https://www.wjgnet.com/1007-9327/full/v28/i26/3218.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i26.3218